N4 Pharma plans for commercialising Nuvec (VIDEO)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec.

Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery systems, the strong commercial point of difference for Nuvec® and the next steps for N4 Pharma.

N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.

You might also enjoy reading  N4 Pharma successful Nuvec double siRNA testing

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
N4 Pharma plans for commercialising Nuvec (VIDEO)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions